<\/p>\n
Udimax 300<\/strong> je ursodeoxycholic acid (UDCA) 300 mg<\/strong> — a hydrophilic bile acid that is the standard of care for primary biliary cholangitis (PBC), cholesterol gallstones in patients unfit for surgery, intrahepatic cholestasis of pregnancy (ICP), bile-acid diarrhoea, and pruritus of cholestatic liver disease<\/strong>. UDCA reduces cholesterol saturation in bile, replaces toxic hydrophobic bile acids in the bile-acid pool, exerts cytoprotective and anti-apoptotic effects on hepatocytes and cholangiocytes, and stimulates bicarbonate-rich choleresis. Standard adult doses range from 10–15 mg\/kg\/day for PBC and gallstones to 14–30 mg\/kg\/day for cholestasis of pregnancy<\/strong>. V\u00fdrobce certifikovan\u00fd WHO-GMP.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Udimax 300 is supplied from a v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/strong>. Ka\u017ed\u00e1 objedn\u00e1vka je diskr\u00e9tn\u011b zas\u00edl\u00e1na po cel\u00e9m sv\u011bt\u011b a je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a> — if it does not arrive within 20 business days, we reship at no cost. UDCA has been on the WHO Essential Medicines List for decades and is the cornerstone of medical therapy for cholestatic liver disease.<\/p>\n UDCA is a naturally occurring hydrophilic 7β-hydroxy bile acid (“the bear bile acid”). When taken orally it enriches the bile-acid pool, replacing toxic hydrophobic acids (chenodeoxycholic, lithocholic) that damage cholangiocytes and hepatocytes in cholestasis. Three actions matter clinically: (1) it reduces biliary cholesterol saturation, dissolving cholesterol gallstones over months; (2) it exerts direct cytoprotective and anti-apoptotic effects on liver cells, reducing immune-mediated damage in PBC; (3) it stimulates a bicarbonate-rich “alkaline tide” choleresis, which protects cholangiocytes from the detergent action of hydrophobic bile acids. Onset of biochemical improvement in PBC is typically 2–6 months.<\/p>\nPro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
Mechanismus \u00fa\u010dinku<\/h2>\n
Indications & doses<\/h2>\n